Quarterly ResultMay 8, 2026, 07:02 AM
ANI Pharma Q1 Net Income +88% to $29.5M; Revenue +20% to $237.5M
AI Summary
ANI Pharmaceuticals reported a significant increase in its first-quarter 2026 financial results, with net income rising by 88% and total net revenues growing by over 20% year-over-year. The company saw strong performance in its Rare Disease and Brands segment, particularly from Cortrophin Gel, and recognized an upfront license fee from a new IP agreement. Operating cash flow also improved substantially.
Key Highlights
- Net income increased 88% to $29.49 million for Q1 2026.
- Total net revenues rose 20.46% to $237.46 million in Q1 2026.
- Diluted EPS grew 85.51% to $1.28 for the quarter.
- Rare Disease and Brands net revenues increased 36.31% to $128.24 million.
- Cortrophin Gel sales were $75.12 million, up 42.13% year-over-year.
- Received $15.0 million upfront license fee from Harmony Agreement.
- Net cash from operating activities was $58.38 million, up 66.82%.
- Cash and cash equivalents stood at $311.18 million as of March 31, 2026.
Price Impact
More from ANIP